Rhythm Pharmaceuticals Inc

13. Nov. 2026, 21:01 UTC

Rhythm Pharmaceuticals, Inc. is trading significantly higher today, with unusually high market volume and currently positioned near the upper end of its one-month range.

12. Nov. 2026, 21:13 UTC

Rhythm Pharmaceuticals, Inc. is trading modestly higher in after-market hours, reflecting a cumulative return of nearly 1% following Thursday's close.

11. Nov. 2026, 22:01 UTC

Rhythm Pharmaceuticals, Inc. is trading lower in after-market hours, having declined below Wednesday's close before recovering slightly from an initial low.

10. Nov. 2026, 20:46 UTC

Rhythm Pharmaceuticals shares are higher as the company reports a significant rise in IMCIVREE sales and speculation of a $124 takeover bid from AstraZeneca.

9. Nov. 2026, 21:07 UTC

Rhythm Pharmaceuticals, Inc. shares advanced, maintaining a higher trajectory since Friday's close, with overall performance robust and trading above its 20-day moving average.

6. Nov. 2026, 23:46 UTC

Rhythm Pharmaceuticals, Inc. is experiencing a slight decline in after-market trading, moving lower from a peak shortly after the market closed.

5. Nov. 2026, 23:31 UTC

Rhythm Pharmaceuticals, Inc. shares are moving lower in after-market trading, reflecting a decline since Thursday's close amid broader market downturns.

4. Nov. 2026, 23:02 UTC

AstraZeneca made a non-binding offer of about $10 billion to acquire Rhythm Pharmaceuticals, proposing $124 per share, according to The Wall Street Journal.

3. Nov. 2026, 21:02 UTC

Rhythm Pharmaceuticals reports a Q3 net loss of $42.4 million, or $0.61 per share, exceeding revenue estimates but falling short of analyst expectations.

2. Nov. 2026, 21:04 UTC

Rhythm Pharmaceuticals, Inc. shares are trading higher today, with notable volume and positioning above their 20-day moving average, despite an earlier pullback.

30. Okt. 2026, 20:08 UTC

Rhythm Pharmaceuticals shares are declining amid a broader downturn in the biotechnology sector, influenced by significant drops in the SPDR S&P Biotech ETF (XBI).

28. Okt. 2026, 20:07 UTC

Rhythm Pharmaceuticals shares are declining amid broader market volatility following the Federal Reserve's decision to maintain interest rates steady.

27. Okt. 2026, 20:07 UTC

Rhythm Pharmaceuticals, Inc. shares are advancing, supported by a broader rally in the biotechnology sector and gains in the SPDR S&P Biotech ETF (XBI).

22. Okt. 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares are advancing amid a significant upward movement in the Biotechnology sub-sector, gaining ground since Wednesday's close.

21. Okt. 2026, 19:46 UTC

Shares of Rhythm Pharmaceuticals Inc fell sharply, trading significantly below its 20-day moving average ahead of its Q3 2026 financial results announcement on November 3, 2026.

20. Okt. 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is trading higher in after-market hours, continuing a trend of three consecutive sessions that have also closed higher.

19. Okt. 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading on Monday.

15. Okt. 2026, 20:07 UTC

Rhythm Pharmaceuticals receives an Overweight rating from JPMorgan, with the price target adjusted to $145.00, reflecting a continued positive outlook.

14. Okt. 2026, 19:56 UTC

Rhythm Pharmaceuticals Inc launched IMCIVREE in Japan as the first approved therapy for acquired hypothalamic obesity, supported by Phase 3 TRANSCEND trial data.

13. Okt. 2026, 22:11 UTC

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading, correlating with slight gains in the Direxion Daily S&P Biotech Bull 3X ETF.

12. Okt. 2026, 19:46 UTC

Rhythm Pharmaceuticals Inc shares fell, fluctuating within a routine range and remaining significantly below its 20-day moving average.

9. Okt. 2026, 20:07 UTC

Rhythm Pharmaceuticals shares advanced after BofA set a new price target of $150, supported by positive feedback on its MC4R franchise for adult hypothalamic obesity.

8. Okt. 2026, 20:01 UTC

RBC Capital raises Rhythm Pharmaceuticals price target to $159.00 from $155.00 while maintaining an Outperform rating, citing strong market performance over five years.

7. Okt. 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, remaining well below their 20-day moving average and significantly lower compared to Tuesday's close.

6. Okt. 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving further below its 20-day moving average since Tuesday's close.

5. Okt. 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of six consecutive daily declines and remaining below its 20-day moving average.

2. Okt. 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions in the red and remaining below the 20-day moving average.

1. Okt. 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is advancing in after-market trading, gaining ground since Thursday's close while currently trading below its 20-day moving average.

29. Sept. 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, declining notably from Monday's close and trading well below its 20-day moving average amid ongoing pressure.

24. Sept. 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell modestly, currently near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.